Drug Profile
Research programme: glycosaminoglycans - Glycan Biosciences
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Glycan Biosciences
- Class Glycoconjugates
- Mechanism of Action Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eosinophilic oesophagitis; Inflammation
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Eosinophilic-oesophagitis in USA
- 28 May 2021 No recent reports of development identified for research development in Inflammation in USA
- 04 Apr 2017 Early research in Eosinophilic oesophagitis in USA (unspecified route)